Chloroquine and hydroxychloroquine in the context of COVID-19
anti-inflammatory, antimalarial, chloroquine, antiviral, hydroxychloroquine, Pandemic, Immunomodulatory, SARS-CoV-2, COVID-19
Chloroquine and closely related structural analogs, employed initially for the treatment of malaria, are now gaining worldwide attention due to the rapidly spreading pandemic caused by severe acute respiratory syndrome-coronavirus-2, named coronavirus disease (COVID) of 2019 (COVID-19). Although much of this attention has a mechanistic basis, the hard efficacy data for chloroquine/hydroxychloroquine in the management of the clinical syndrome of COVID-19 have been limited thus far. This review aims to present the available in vitro and clinical data for the role of chloroquine/ hydroxychloroquine in COVID-19 and attempts to put them into perspective, especially in relation to the different risks/benefits particular to each patient who may require treatment.
Aparna Wagle Shukla, Hiren J. Mehta, Kartikeya Cherabuddi, Lennox K. Archibald, Ashutosh M Shukla